Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Hair loss treatments like Minoxidil, finasteride, and potential mRNA therapies are discussed. There is skepticism about targeting specific genes due to the complex genetic nature of hair loss.

Finasteride and oral minoxidil effectively maintain a youthful appearance and full head of hair, despite genetic predispositions to balding. The discussion also considers the impact of DHT blockers on masculinity and aging, with lifestyle choices like sunscreen use and a vegetarian diet mentioned.

Evidence-based treatments for androgenic alopecia, such as minoxidil, finasteride, low-level laser light therapy, dutasteride, platelet-rich plasma, and topical ketoconazole. It discusses the efficacy, safety, and mechanism of action of these treatments, as well as future developments in understanding this polygenic condition.

Minoxidil and finasteride have stabilized hair loss but not significantly improved regrowth. The user is considering dutasteride, oral Minoxidil, or a hair transplant for better results.

A 33-year-old experienced hairline improvement using finasteride and minoxidil, later stopping minoxidil while continuing ketoconazole shampoo. Initial side effects included shedding, reduced libido, and anxiety, but these resolved, leading to a full hairline recovery.

The conversation humorously discusses the unfairness of hair loss, highlighting various treatments like finasteride, minoxidil, red light therapy, and experimental drugs, while contrasting with people who have great hair despite unhealthy lifestyles. The original poster mentions experiencing side effects from switching to oral finasteride.

Topical finasteride that doesn't penetrate the skin could potentially treat hair loss without side effects. Current challenges include finding a formulation that remains on the scalp without increasing blood levels.

The user is seeking alternatives to propylene glycol and glycerin for mixing with RU58841 due to allergies and greasiness. Suggestions include reducing glycerin and considering stemoxydine as a solvent.

Finasteride is effective for DHT/AR-driven hair loss but not for chromosome 20-driven cases, where treatments like minoxidil, prostaglandin analogs, and low-level laser therapy may be more beneficial. Genetic testing can help determine the underlying cause of hair loss to tailor treatment effectively.

Exploring different treatments for hair loss, such as cosmeRNA and HMI-115 which are small interference messenger RNA that inhibits the DHT receptor and an antibody that binds to the prolactin (PRL) receptor respectively; and researching mechanism and environment of hyperresponders.

Oral hyaluronic acid is not beneficial for hair, as it gets broken down in the stomach and has no strong evidence supporting its effectiveness. The user is taking finasteride, dutasteride, and topical minoxidil for hair loss, but combining finasteride and dutasteride is considered redundant.

The conversation discusses CRISPR-on & CRISPR-off as a potential cure for baldness, contrasting it with hair cloning and other treatments like Minoxidil, finasteride, and RU58841. It also mentions the potential of mRNA for gene expression control and the prioritization of gene editing for severe genetic conditions.

Male-pattern baldness might increase UVB exposure on the scalp, potentially affecting vitamin D and skeletal health. The hypothesis is debated, with some seeing it as a minor benefit in specific contexts.

The user plans to stop finasteride after three months, believing hair loss isn't due to DHT, and will continue with oral minoxidil, microneedling, and ketoconazole shampoo. They suspect stress and poor nutrition are the main causes and seek opinions on DHT blockers' effectiveness.

Hair loss is linked to cellular physiology and the IGF-1 to TGF-B1 ratio, not just androgen sensitivity. The theory lacks evidence, while finasteride and minoxidil are effective treatments.

The conversation discusses hair loss treatments, focusing on finasteride, minoxidil, and other options like PRP and ketoconazole. It highlights the importance of asking specific questions during a dermatology visit to determine the cause of hair loss and appropriate treatments.

The conversation discusses the lack of public information on the chemical structure of PP405, a hair loss treatment, and the challenges of synthesizing it without a patent. It also explores a patent related to hydrogen-based topical formulations for reducing oxidative stress and inflammation.

Hair loss theory involves 3alpha-hydroxysteroid reductase (3AHD) converting DHT to androstenol. Discussion explores potential treatments and encourages more research.

Copper peptides for hair loss, discussing carriers for skin penetration and recommending a product from Amazon.

The conversation is about the use of emulsifiers in a propylene glycol and ethanol solvent for minoxidil formulations. Emulsifiers are typically around 1-3% of the total vehicle and help disperse the contents.

The conversation is about finding a safe carrier for topical antiandrogens like finasteride, kx-826, RU58841, and dutasteride to minimize systemic absorption and side effects. The user experiences side effects from these treatments and is seeking advice on carriers that reduce these effects.

Liposomal carriers for topical finasteride and minoxidil may reduce side effects and scalp irritation compared to traditional ethanol and propylene glycol carriers. The main drawback is the higher cost.

Liposomal carriers for topical finasteride offer better targeting, reduced side effects, and less irritation compared to alcohol-based solutions, but availability and cost may limit their use. Minoxidil can dissolve in liposomal carriers, enhancing delivery and stability.

The conversation discusses whether oils like jojoba, argan, and castor oil are effective carriers for delivering treatments like Minoxidil, finasteride, and RU58841 through the skin. The user questions if these oils could be a less oily alternative to ethanol/PG for daily application.

OP is considering using Stemoxydine or the Ordinary Multi Peptide Hair Serum as a carrier for topical finasteride, avoiding minoxidil due to palpitations. They plan to crush finasteride pills into a 30 ml solution.